| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 10/12/2024 | 22:34 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SLRN | ACELYRIN Inc |
| 10/12/2024 | 22:30 | GlobeNewswire Inc. | ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis | NASDAQ:SLRN | ACELYRIN Inc |
| 13/11/2024 | 23:26 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:SLRN | ACELYRIN Inc |
| 13/11/2024 | 22:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:SLRN | ACELYRIN Inc |
| 13/11/2024 | 22:00 | GlobeNewswire Inc. | ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights | NASDAQ:SLRN | ACELYRIN Inc |
| 08/11/2024 | 20:17 | Edgar (US Regulatory) | Form SC 13G - Statement of Beneficial Ownership by Certain Investors | NASDAQ:SLRN | ACELYRIN Inc |
| 06/11/2024 | 22:00 | GlobeNewswire Inc. | ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024 | NASDAQ:SLRN | ACELYRIN Inc |
| 04/11/2024 | 22:11 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:SLRN | ACELYRIN Inc |
| 16/10/2024 | 13:00 | GlobeNewswire Inc. | ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease | NASDAQ:SLRN | ACELYRIN Inc |
| 19/09/2024 | 13:00 | GlobeNewswire Inc. | ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 | NASDAQ:SLRN | ACELYRIN Inc |
| 10/09/2024 | 13:00 | GlobeNewswire Inc. | ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Sur | NASDAQ:SLRN | ACELYRIN Inc |
| 22/08/2024 | 13:00 | GlobeNewswire Inc. | ACELYRIN, INC. to Participate in Upcoming Investor Conferences | NASDAQ:SLRN | ACELYRIN Inc |
| 13/08/2024 | 22:00 | GlobeNewswire Inc. | ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results | NASDAQ:SLRN | ACELYRIN Inc |
| 06/08/2024 | 22:30 | GlobeNewswire Inc. | ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024 | NASDAQ:SLRN | ACELYRIN Inc |
| 05/06/2024 | 13:00 | GlobeNewswire Inc. | ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024 | NASDAQ:SLRN | ACELYRIN Inc |
| 29/05/2024 | 13:00 | GlobeNewswire Inc. | ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024 | NASDAQ:SLRN | ACELYRIN Inc |
| 25/05/2024 | 01:12 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SLRN | ACELYRIN Inc |
| 18/05/2024 | 01:05 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:SLRN | ACELYRIN Inc |
| 09/05/2024 | 14:14 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:SLRN | ACELYRIN Inc |
| 09/05/2024 | 14:01 | GlobeNewswire Inc. | ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones | NASDAQ:SLRN | ACELYRIN Inc |
| 09/05/2024 | 14:00 | GlobeNewswire Inc. | ACELYRIN, INC. Announces Leadership Transition | NASDAQ:SLRN | ACELYRIN Inc |
| 29/04/2024 | 22:05 | GlobeNewswire Inc. | ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 | NASDAQ:SLRN | ACELYRIN Inc |
| 28/03/2024 | 21:05 | GlobeNewswire Inc. | ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights | NASDAQ:SLRN | ACELYRIN Inc |
| 27/03/2024 | 21:01 | GlobeNewswire Inc. | Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million | NASDAQ:SLRN | ACELYRIN Inc |
| 20/03/2024 | 12:00 | GlobeNewswire Inc. | ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease | NASDAQ:SLRN | ACELYRIN Inc |
| 11/03/2024 | 13:02 | GlobeNewswire Inc. | ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis | NASDAQ:SLRN | ACELYRIN Inc |
| 11/03/2024 | 13:00 | GlobeNewswire Inc. | ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients | NASDAQ:SLRN | ACELYRIN Inc |
| 15/02/2024 | 22:05 | GlobeNewswire Inc. | ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications | NASDAQ:SLRN | ACELYRIN Inc |
| 12/01/2024 | 11:45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN) | NASDAQ:SLRN | ACELYRIN Inc |
| 20/12/2023 | 22:30 | GlobeNewswire Inc. | ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors | NASDAQ:SLRN | ACELYRIN Inc |